Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment.

Blood cells, molecules & diseases·2013

Same author

Relationship between neonatal screening results by HPLC and the number of α-thalassaemia gene mutations; consequences for the cut-off value.

Journal of medical screening·2011

Same author

Red cell pyruvate kinase deficiency in Southern Sardinia.

Blood cells, molecules & diseases·2010

Same author

The role of haemoglobin A(2) testing in the diagnosis of thalassaemias and related haemoglobinopathies.

Journal of clinical pathology·2008

Same author

Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major.

British journal of haematology·2008

Same author

Thalassaemia and glucose-6-phosphate dehydrogenase screening in 13- to 14-year-old students of the Sardinian population: preliminary findings.

Community genetics·2008

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Deferiprone chelation therapy for thalassemia major.

R Galanello¹, S Campus

¹Dipartimento di Scienze Biomediche e Biotecnologie, Ospedale Regionale Microcitemie, Azienda Sanitaria Locale 8, Università di Cagliari, Cagliari, Italia. renzo.galanello@mcweb.unica.it

Acta Haematologica

|November 13, 2009

Summary

Deferiprone (DFP) effectively treats iron overload in thalassemia major patients, showing comparable efficacy to desferoxamine (DFO) and superior results for heart conditions. Combination therapy offers an alternative for severe cases.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Related Experiment Videos

Last Updated: Jun 18, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Area of Science:

Hematology
Pharmacology
Internal Medicine

Background:

Iron overload is a significant complication in thalassemia major patients.
Effective iron chelation therapy is crucial for managing morbidity.

Purpose of the Study:

To evaluate the efficacy and safety of Deferiprone (DFP) for iron overload in thalassemia major.
To compare DFP with desferoxamine (DFO) and assess combination therapy.

Main Methods:

Comparative studies analyzing iron removal efficacy.
Retrospective and prospective studies assessing treatment outcomes, particularly myocardial siderosis.
Evaluation of combination therapy with DFP and DFO.

Main Results:

Deferiprone (DFP) demonstrates efficacy in iron removal, comparable to desferoxamine (DFO).
DFP monotherapy showed superior effectiveness in treating myocardial siderosis compared to DFO.
Combination therapy with DFP and DFO is tolerable and effective for severe iron overload.

Conclusions:

Deferiprone is an effective oral iron chelator for thalassemia major.
DFP offers advantages over DFO in specific clinical scenarios, including myocardial siderosis.
Combination therapy provides a viable option for complex iron overload management.